Cour and Takeda Partner to Treat Celiac Disease
Palo Alto – December 10, 2015 –Cooley advised Cour Pharmaceutical on its partnership with Takeda Pharmaceutical to research and develop novel immune therapies for the potential treatment of celiac disease and other gastrointestinal diseases.
According to Takeda's press release: "The partnership will focus on using nanotechnologies based on Cour's Tolerizing Immune Modifying nanoparticle (TIMP) platform."
Cour will receive upfront and success-based milestone payments from Takeda leading to an exclusive option to acquire a global license to the TIMP program after the completion of the Phase 2a clinical trial. Cour will also receive royalties on sales of any successful commercialized products resulting from the partnership. Takeda will have the option to collaborate on up to three additional TIMP compounds each with development, regulatory, and sales milestones and royalties on sales.
Cour is a private development stage pharmaceutical company harnessing the power of nano-biotechnology to create novel therapeutics addressing difficult-to treat immune diseases. Takeda is a global research-based pharmaceutical company and is a leader in gastroenterology.
The Cooley team advising Cour on its partnership agreement included Lila Hope and Jennifer Raab. Erich Veitenheimer, Mike Garelick and Alyson Fuller advised Cour on the IP diligence.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 850 lawyers across 12 offices in the United States, China and Europe
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.